Form 4: Contineum CSO Sells Shares Under 10b5-1 Plan

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock on January 5, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), reported sales of Class A Common Stock.
• On January 5, 2026, a total of 4,170 shares were sold in two separate transactions.
• The first transaction involved 3,670 shares sold at a weighted average price of $10.3483, with prices ranging from $10.000 to $10.955.
• The second transaction involved 500 shares sold at a weighted average price of $11.1298, with prices ranging from $11.00 to $11.34.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Lorrain on September 23, 2025.
• Following these transactions, Mr. Lorrain directly beneficially owns 160,222 shares of Class A Common Stock and indirectly owns 6,842 shares through his spouse.

Sentiment

Score: 5

Explanation: The filing reports pre-scheduled insider stock sales under a 10b5-1 plan, which are generally considered neutral events as they are not typically driven by immediate market sentiment or new information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by some investors as a lack of conviction in the company's near-term stock price appreciation, although this is not always the case for pre-planned sales.

Future Outlook

NA

Industry Context

Insider sales, particularly those executed under pre-arranged 10b5-1 trading plans, are a common occurrence across all industries, including biotechnology and pharmaceuticals. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, helping them manage personal finances while avoiding accusations of trading on material non-public information. Such sales do not necessarily reflect a change in the insider's outlook on the company's future prospects.

Stakeholder Impact

• Shareholders: May observe the reduction in direct insider ownership, though the pre-planned nature of the sale (10b5-1 plan) mitigates concerns compared to an unplanned sale.

Key Dates

Keywords

Contineum Therapeutics, CTNM, Insider Trading, Form 4, Stock Sale, Daniel S. Lorrain, 10b5-1 Plan, Chief Scientific Officer